Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Biochemicals supplier Cayman Chemical is joining with the University of Texas MD Anderson Cancer Center and Fannin Innovation Studio to form ACF Pharmaceuticals, a drug company that will pursue small-molecule inhibitors for inflammation-induced cancers such as melanoma and colon cancer. Under the pact, Cayman will develop molecules that modulate the cyclooxygenase (COX) pathway. MD Anderson will evaluate them, and Fannin, a Houston-based life science commercialization firm, will provide funding and management.
This article has been sent to the following recipient: